Discovery of 2-oxopiperazine dengue inhibitors by scaffold morphing of a phenotypic high-throughput screening hit

Bioorg Med Chem Lett. 2017 Mar 15;27(6):1385-1389. doi: 10.1016/j.bmcl.2017.02.005. Epub 2017 Feb 4.

Abstract

A series of 2-oxopiperazine derivatives were designed from the pyrrolopiperazinone cell-based screening hit 4 as a dengue virus inhibitor. Systematic investigation of the structure-activity relationship (SAR) around the piperazinone ring led to the identification of compound (S)-29, which exhibited potent anti-dengue activity in the cell-based assay across all four dengue serotypes with EC50<0.1μM. Cross-resistant analysis confirmed that the virus NS4B protein remained the target of the new oxopiperazine analogs obtained via scaffold morphing from the HTS hit 4.

Keywords: 2-Oxopiperazine; Cell-based screen; Dengue virus; NS4B; Scaffold morphing.

MeSH terms

  • Antiviral Agents / pharmacology*
  • Cell Line
  • Dengue Virus / drug effects*
  • Drug Discovery
  • High-Throughput Screening Assays
  • Humans
  • Piperazines / pharmacology*
  • Structure-Activity Relationship

Substances

  • Antiviral Agents
  • Piperazines